Impact of KRAS^G12D subtype and concurrent pathogenic mutations on advanced non-small cell lung cancer outcomes.

ABSTRACT:

Purpose

Mutations in the Kirsten rat sarcoma viral (KRAS) oncogene constitute a significant driver of lung adenocarcinoma, present in 10-40% of patients, which exhibit heterogeneous clinical outcomes, mainly driven by concurrent genetic alterations. However, characterization of KRAS mutational subtypes and their impact on clinical outcomes in Latin America is limited.

Methods

A cohort study was conducted at the National Cancer Institute (INCan) of Mexico. Individuals with advance-staged of adenocarcinoma and KRAS mutations, detected by next-generation sequencing, having undergone at least one line of therapy were included for analysis. Clinical and pathological characteristics were retrieved from institutional database from June 2014 to March 2023.

Results

KRAS was id

SUBMITTER: Caballe-Perez E 

PROVIDER: S-EPMC10981588 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature